Section 14. Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Securities.
As of the date hereof, there were outstanding 9,200,000 Series X Preferred Shares, 8,000,000 Series Y Preferred Shares and 13,000,000 Series Z Preferred Shares.
The Company does not, and does not believe after reasonable inquiry that any of its executive officers and directors or any associates or majority-owned subsidiaries of the Company, beneficially owns any of the Securities.
Based on the Company’s records and on information provided to it by its executive officers, directors, affiliates and subsidiaries, neither the Company nor any of its affiliates or subsidiaries nor, to its knowledge after reasonable inquiry, any of the Company’s or its subsidiaries’ directors or executive officers, nor any associates or subsidiaries of any of the foregoing, have effected any transactions involving the Securities during the sixty days prior to November 21, 2022.
The Company entered into a Deposit Agreement, dated September 12, 2017, among the Company, American Stock Transfer & Trust Company, LLC, as depositary, and the holders from time to time of the depositary receipts described therein, governing the terms of the Series X Preferred Shares. The terms of the 5.250% Cumulative Preferred Stock, Series X, stated value $25,000 per share, of the Company underlying the Series X Preferred Shares are governed by the charter of the Company.
The Company entered into a Deposit Agreement, dated November 30, 2017, among the Company, American Stock Transfer & Trust Company, LLC, as depositary, and the holders from time to time of the depositary receipts described therein, governing the terms of the Series Y Preferred Shares. The terms of the 5.200% Cumulative Preferred Stock, Series Y, stated value $25,000 per share, of the Company underlying the Series Y Preferred Shares are governed by the charter of the Company.
The Company entered into a Deposit Agreement, dated October 24, 2019, among the Company, American Stock Transfer & Trust Company, LLC, as depositary, and the holders from time to time of the depositary receipts described therein, governing the terms of the Series Z Preferred Shares. The terms of the 4.875% Cumulative Preferred Stock, Series Z, stated value $25,000 per share, of the Company underlying the Series Z Preferred Shares are governed by the charter of the Company.
Except as otherwise described in this Offer to Purchase, neither the Company nor, to its knowledge after reasonable inquiry, any of its affiliates, directors or executive officers, is a party to any contract, arrangement, understanding or relationship with any other person relating, directly or indirectly, to the Offers or with respect to any of the Securities, including, but not limited to, any contract, arrangement, understanding or relationship concerning the transfer or the voting of securities, joint ventures, loan or option arrangements, puts or calls, guaranties of loans, guaranties against loss or the giving or withholding of proxies, consents or authorizations.
Section 15. Legal Matters; Regulatory Approvals.
The Company is not aware of any license or regulatory permit that appears material to its business that might be adversely affected by its acquisition of Securities as contemplated by the Offers. Nor is the Company aware of any approval or other action by any government or governmental, administrative or regulatory authority or agency, domestic, foreign or supranational that would be required for the acquisition of Securities by the Company as contemplated by the Offers other than those that have been obtained. Should any approval or other action be required, the Company presently contemplates that it will seek that approval or other action. The Company is unable to predict whether it will be required to delay the acceptance for purchase of or payment for Securities tendered under the Offers pending the outcome of any such matter. There can be no assurance that any approval or other action, if needed, would be obtained or would be obtained without substantial cost or conditions or that the failure to obtain the approval or other action might not result in adverse consequences to its
33